News | February 25, 2015

Optimal Tissue Debulking Protocol Defined for Treating In-Stent Restenosis

Testing performed with Boston Scientific’s Jetstream Navitus Atherectomy Device

Boston Scientific, Jetstream, CBSET, atherectomy, PAD

February 25, 2015 — CBSET, a not-for-profit preclinical research institute, announced that its scientists have defined the optimal tissue debulking protocol for treating in-stent restenosis (ISR) with Boston Scientific’s Jetstream Navitus atherectomy device. These findings were disclosed at the Cardiovascular Research Technologies 2015 annual scientific meeting (CRT 2015) in Washington, D.C.

The study (“Optimal Number of Runs Using the Jetstream Navitus Device to Achieve Maximum Tissue Debulking of In-Stent Restenosis in a Porcine Stent/Balloon Injury Overstretch Model”) determined that the Boston Scientific device achieved optimal tissue debulking after two blade-up (BU) runs, with no further gain in debulking after the second run. This study also confirmed that stent damage was minimal after the procedure, with no disruption to stent struts or stent integrity. Prior to this study, the number of runs needed to achieve optimal tissue debulking in ISR using the Jetstream Navitus device was unknown.

“Now we may proceed to translate these findings into clinical data, with the goal that optimal tissue removal or debulking will translate into (1) better patient outcomes, and (2) ideal coupling with adjunctive therapies such as drug-coated balloons. We believe that the optimal debulking process will give physicians the best acute procedural results and hopefully better long-term outcomes,” concluded the study’s principal investigator, Nicolas W. Shammas, M.D., president and research director, Midwest Cardiovascular Research Foundation.

The results of two related studies also were disclosed at CRT 2015:

  • “Minimal Plaque Surface Area and Minimal Luminal Area Needed for Effective Atherectomy using the JetStream Navitus in Treating In-Stent Restenosis of Femoral Artery in a Porcine Model”
  • “Intravascular Ultrasound Assessment of the Optimal Number of Runs Using the JetStream Navitus Device to Achieve Maximum Tissue Debulking in Femoral Artery in-Stent Restenosis Porcine Model”

 

For more information: www.cbset.org

Related Content

News | Peripheral Artery Disease (PAD) | November 14, 2019
November 7, 2019 — Ultrasoundplasty before angioplasty for below-the-knee lesions (BTK) lesions may improve clinical
News | Peripheral Artery Disease (PAD) | November 14, 2019
November 14, 2019 — There were positive results in the TANGO Trial is a phase 2, dose escalation, double-blinded tria
The LimFlow procedure permanently bypasses unreconstructable arteries and leverages healthier veins as a conduit to create new routes to perfuse tissue in the foot.  #VIVA #VIVA19 #VIVA2019

The LimFlow procedure permanently bypasses unreconstructable arteries and leverages healthier veins as a conduit to create new routes to perfuse tissue in the foot. 

News | Peripheral Artery Disease (PAD) | November 14, 2019
November 14, 2019 — Results were positive for the multicenter PROMISE I Trial represents the first human use in the U
Eluvia and Ranger PAD devices from Boston Scientific. #VIVA19 #VIVA2019 #VIVA
News | Peripheral Artery Disease (PAD) | November 06, 2019
November 6, 2019 – Boston Scientific announced positive data for two of its devices within the peripheral drug-elutin
FDA Panel Recommends Continued Use of Paclitaxel-coated Peripheral Devices
Feature | Peripheral Artery Disease (PAD) | August 28, 2019 | Jeff Zagoudis, Associate Editor
The U.S. Food and Drug Administration (FDA) released an updated MedWatch Alert this month on the safety of paclitaxel-...
New Report Says Concept Medical Positioned to Disrupt Peripheral Market
News | Peripheral Artery Disease (PAD) | August 27, 2019
Concept Medical was recently granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA)...
PAD Intervention Patients on Statins Less Likely to Face Amputation
News | Peripheral Artery Disease (PAD) | August 23, 2019
Patients with peripheral artery disease (PAD) were significantly less likely to face amputation after surgical...
Concept Medical Granted FDA Breakthrough Device Designation for MagicTouch PTA Sirolimus Coated Balloon
News | Peripheral Artery Disease (PAD) | August 14, 2019
Concept Medical Inc. (CMI) has been granted "Breakthrough Device Designation" from the U.S. Food and Drug...
New AHA Statement Highlights Need for Early Diagnosis, Treatment With Critical Limb IschemiaCTA image of a patient with severe peripheral artery disease (PAD) viewed on a tablet device using Siemens syngo.via webviewer.

CTA image of a patient with severe peripheral artery disease (PAD) viewed on a tablet device using Siemens syngo.via webviewer. PAD can lead to CLI.

News | Peripheral Artery Disease (PAD) | August 13, 2019
Non-invasive techniques and devices for assessing blood flow and other diagnostic considerations for people with ...
Endovascular-first Approach Equal to Open Surgery in Avoiding Amputation for Critical Limb Ischemia
News | Peripheral Artery Disease (PAD) | August 01, 2019
Less-invasive procedures to open severely clogged leg arteries were as good at helping people survive and avoid...
Overlay Init